# Todd C. Davis

> Todd C. Davis is a funding round investor at Ligand Pharmaceuticals backing Biopharma. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Ligand Pharmaceuticals](https://shizune.co/investors/profile/ligand-pharmaceuticals)
- Location: Jupiter, United States
- Total investments: 1
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/toddcdavis2

Todd C. Davis is a funding round investor at Ligand Pharmaceuticals in Jupiter focused on Biopharma and Life Science. Todd Davis is the Chief Executive Officer & Director of Ligand Pharmaceuticals. He previously worked at BioDelivery Sciences International as a Director. Todd Davis attended Harvard Business School.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 1 | 100% |
| Life Science | 1 | 100% |
| Biotechnology | 1 | 100% |
| Pharmaceutical | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Castle Creek Biosciences | Castle Creek Biosciences is focused on developing and commercializing novel, personalized gene therapies for rare skin and connective tissue disorders with high unmet need. It was founded in 2015 and headquartered in Pennsylvania, United States. | $75M |  |  |  |

1 of 1 investments shown.

## About Ligand Pharmaceuticals

VC Fund · San Diego, United States

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporatecost structure. Ligand's goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified, and lower-risk business than a typical biotech company. Ligand business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation, and partnering. Ligand partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management, and commercialization) to ultimately generate Ligand revenue.

5 contacts available at Ligand Pharmaceuticals.

| Name | Title | Profile |
| --- | --- | --- |
| Bob Chen | Director, Systems Engineering and Site Head | https://shizune.co/investors/profile/bob-chen-4a5d |
| David J. Mangelsdorf | Team Member | https://shizune.co/investors/profile/david-j-mangelsdorf |
| John Higgins | CEO | https://shizune.co/investors/profile/john-l-higgins |
| Richard Baxter | Senior Vice President of Investment Operations | https://shizune.co/investors/profile/richard-baxter-8ec4 |
| Todd C. Davis | Chief Executive Officer & Director | https://shizune.co/investors/profile/todd-c-davis |

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Todd C. Davis invest in?

Todd C. Davis invests primarily in Biopharma, Life Science and Biotechnology startups, most often at Funding Round stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co